| Old Articles: <Older 7191-7200 Newer> |
|---|
 |
The Motley Fool
February 23, 2011
Brian Orelli |
Gilead Gears Up to Fight Cancer Gilead has been infected by the diversification bug.   |
The Motley Fool
February 22, 2011
Brian Orelli |
Biogen and Elan's Growing Problem More cases of potentially lethal PML. |
The Motley Fool
February 22, 2011
Ryan McBride |
Forest Labs Snaps Up Clinical Data This deal is the latest proof that drug developers with FDA-approved treatments remain hot buyout targets in a pharma industry that is starved for new products to replace brand-name drugs. |
The Motley Fool
February 22, 2011
Brian Orelli |
Timber! Clinical Data Falls. Forest Labs cuts down Clinical Data. Clinical Data announced today that it agreed to be purchased by Forest Labs for $30 per share. |
The Motley Fool
February 22, 2011
Brian Orelli |
A Billion-Dollar Market to Open "Very Soon" Biosimilar drugs are finally coming to the U.S. |
The Motley Fool
February 22, 2011
Luke Timmerman |
Gilead Buys Calistoga Pharma, Making Move Into Cancer Drugs Gilead diversifies with Calistoga purchase. |
The Motley Fool
February 22, 2011
Jared Cummans |
Tuesday's ETF to Watch: Medical Devices Fund Medtronic reports earnings today. |
The Motley Fool
February 18, 2011
Seth Jayson |
Should You Get Out of Agilent Technologies Before Next Quarter? The numbers don't paint a clear picture. For the last fully reported fiscal quarter, Agilent Technologies' year-over-year revenue grew by 25.2%, and its AR grew by 36.0%. That's a yellow flag. |
The Motley Fool
February 18, 2011
Sean Williams |
HealthSouth: Bargain Buy or Value Trap? Is there a real turnaround, or will the debt load get the best of this company? |
The Motley Fool
February 18, 2011
John Keeling |
An Inside Look at Biotech Investing, Part 2 More on investing in "baby biotechs." |
| <Older 7191-7200 Newer> Return to current articles. |
